Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Rhea-AI Summary

BioNTech (Nasdaq:BNTX) and Bristol Myers Squibb reported interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 trial of bispecific immunomodulator pumitamig plus chemotherapy in first-line advanced non-small cell lung cancer.

The regimen showed confirmed objective response rates up to 72.7% by subtype and up to 100% at high PD-L1 expression, with a 100% disease control rate and a manageable safety profile, and is now being advanced in three global Phase 3 NSCLC trials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• cORR 57.1% in non-squamous and 68.4% in squamous NSCLC at Phase 2 interim
• Lower pumitamig dose showed higher cORR: 63.6% non-squamous, 72.7% squamous
• cORR by PD-L1 level: 47.6% (<1%), 77.8% (1–49%), 100% (≥50%)
• Disease control rate reported at 100% among 40 response-evaluable patients
• Three global Phase 3 NSCLC trials with pumitamig are actively enrolling

Negative

• Grade ≥3 treatment-related adverse events in 48.8% of patients
• Pumitamig-related Grade ≥3 TRAEs in 23.3% of patients
• Treatment discontinuation due to TRAEs in 9.3% of patients
• Immune-related AEs in 37.2% of patients; Grade ≥3 irAEs in 4.7%
• Bleeding events in 20.9% of patients, including one Grade 3 case

Market Context

This announcement highlights interim Phase 2 data for pumitamig in first-line NSCLC, with confirmed ...

Analysis

This announcement highlights interim Phase 2 data for pumitamig in first-line NSCLC, with confirmed objective response rates up to 72.7% by subtype and a 100% disease control rate, alongside a manageable safety profile. It builds on BioNTech’s broader late-stage oncology strategy and ongoing Phase 3 ROSETTA Lung-02 and related trials. Investors may monitor subsequent Phase 3 readouts, evolution of the lung program, and how these data integrate with prior ASCO-related disclosures.

Key Figures

cORR non-squamous (low dose): 63.6% cORR squamous (low dose): 72.7% cORR non-squamous (overall): 57.1% +5 more

8 metrics

cORR non-squamous (low dose) 63.6% Confirmed objective response rate at lower pumitamig dose in non-squamous NSCLC

cORR squamous (low dose) 72.7% Confirmed objective response rate at lower pumitamig dose in squamous NSCLC

cORR non-squamous (overall) 57.1% Overall confirmed objective response rate in non-squamous NSCLC

cORR squamous (overall) 68.4% Overall confirmed objective response rate in squamous NSCLC

Disease control rate 100% Disease control rate for pumitamig plus chemotherapy across NSCLC subtypes

cORR TPS < 1% 47.6% Confirmed objective response rate in PD-L1 TPS < 1% subgroup

cORR TPS 1–49% 77.8% Confirmed objective response rate in PD-L1 TPS 1–49% subgroup

cORR TPS ≥ 50% 100% Confirmed objective response rate in PD-L1 TPS ≥ 50% subgroup

Historical Context

5 past events · Latest: May 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 22	Oncology ASCO preview	Positive	+1.3%	Preview of ASCO data including pumitamig and other late-stage oncology assets.
May 15	AGM approvals	Positive	-0.8%	All AGM items approved and Supervisory Board expanded with oncology expertise.
May 07	ADS buyback launch	Positive	-2.4%	Authorization of new $1.0 billion ADS repurchase program through May 2027.
May 05	Q1 2026 earnings	Neutral	-3.9%	Q1 2026 loss with strong cash position and multiple pivotal pumitamig trials initiated.
Apr 21	Earnings date notice	Neutral	+6.1%	Announcement of Q1 2026 results date and investor call logistics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mostly been positive or strategic, yet price reactions have been mixed, with several positive corporate updates met by short-term declines.

Recent Company History

Over the past months, BioNTech has highlighted its oncology pivot, including late-stage data to be shown at ASCO, shareholder approval of all AGM items, a new $1.0 billion ADS repurchase program, and Q1 2026 results with €118.1m revenues and a €531.9m net loss. While the earlier ASCO preview for pumitamig saw a 1.33% gain, other constructive updates, such as buybacks and guidance reaffirmation, coincided with short-term declines, underscoring uneven near-term reactions to otherwise supportive news.

Key Terms

non-small cell lung cancer, pd-l1, vegf-a, bispecific immunomodulator, +4 more

8 terms

non-small cell lung cancer medical

"in patients with non-small cell lung cancer in ROSETTA Lung-02 trial"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

pd-l1 medical

"across PD-L1 expression levels and subtypes, highlighting its potential"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

vegf-a medical

"pd-l1xvegf-a bispecific immunomodulator pumitamig"

VEGF-A is a naturally occurring protein that acts like a growth signal for new blood vessels, helping tissues develop or repair their blood supply. It matters to investors because many drugs and diagnostics target or measure VEGF-A to treat conditions such as cancers and eye diseases, so changes in clinical trial results, regulatory decisions, or new therapies related to VEGF-A can directly affect the value and prospects of companies developing those treatments.

bispecific immunomodulator medical

"pd-l1xvegf-a bispecific immunomodulator pumitamig"

A bispecific immunomodulator is a type of drug, usually a protein, engineered to attach to two different molecules at once and adjust how the immune system works. Think of it as a two-headed key that can unlock or block two locks to steer the immune response more precisely than single-target drugs. Investors care because this dual-action design can boost effectiveness or reduce side effects, but it also adds development complexity, clinical risk, and potential regulatory hurdles that affect value.

objective response rate medical

"showing a cORR of 63.6% for non-squamous and 72.7% for squamous"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

disease control rate medical

"with a disease control rate (“DCR”) of 100%."

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

treatment-related adverse events medical

"Grade ≥ 3 treatment-related adverse events (“TRAEs”) were reported"

Treatment-related adverse events are harmful or unwanted health effects that doctors or regulators determine were caused by a drug, vaccine, device, or other medical therapy. Investors care because how often and how severe these side effects are can shape regulatory approval, labeling, sales potential and legal risk — similar to how product defects can stop or damage a company's ability to sell an item.

immune-related aes medical

"Immune-related AEs (“irAEs”) occurred in 16 (37.2%) patients"

Immune-related adverse events are unwanted side effects that occur when a treatment stimulates the immune system so strongly that it attacks healthy tissues—like friendly fire from an overexcited defense force. Investors should care because these reactions can change a drug’s safety profile, slow or stop clinical trials, affect regulatory approval, and influence future sales and legal risk, all of which can materially alter a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care
• Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes
• Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials

MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”).

The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%). The data are being presented today as a rapid oral presentation (abstract #8513) at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago.

“Despite significant immuno-oncology advances in the treatment of  non-small cell lung cancer, most advanced diseases relapse on or after a PD-(L)1 checkpoint inhibitor treatment,¹ indicating that targeting this immunologic pathway alone is insufficient to achieve durable responses,” said Solange Peters, M.D., Ph.D., Lead Investigator and Director of Oncology at the University Hospital of Lausanne, Switzerland. “I am encouraged by the efficacy signal with this bispecific approach, showing robust responses across subtypes and PD-L1 levels, supporting the continued investigation of pumitamig and its potential to deliver improved outcomes for a broad range of patients with NSCLC.”

The Phase 2 part of the ROSETTA Lung-02 trial evaluated pumitamig in two dose levels, in combination with chemotherapy. At this interim analysis at the April 13, 2026 data cut-off, among 40 response-evaluable patients with a median follow-up of 9.0 months, pumitamig plus chemotherapy showed a confirmed objective response rate (“cORR”) of 57.1% in patients with non-squamous NSCLC and 68.4% with squamous NSCLC with a disease control rate (“DCR”) of 100%. Encouraging anti-tumor activity was observed at both dose levels, with higher response rates at the lower dose showing a cORR of 63.6% for non-squamous and 72.7% for squamous NSCLC. Results were high at each PD-L1 expression level (cORR: 47.6% TPS ˂ 1%; 77.8% TPS 1 – 49 %; 100% TPS ≥ 50%).

Pumitamig plus chemotherapy demonstrated a manageable safety profile with a low discontinuation rate. Grade ≥ 3 treatment-related adverse events (“TRAEs”) were reported in 48.8% of patients and were considered pumitamig-related in 23.3%, leading to treatment discontinuation in four (9.3%) patients. Immune-related AEs (“irAEs”) occurred in 16 (37.2%) patients and grade ≥ 3 irAEs in two (4.7%) patients. Bleeding events were reported in nine (20.9%) patients, with only one event being grade 3.

“The data we are presenting today provide further evidence of the potential of pumitamig to enhance anti-tumor responses in advanced lung cancer, one of the most challenging indications, by simultaneously targeting PD-L1 and VEGF-A with a single molecule,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “Pumitamig has consistently shown efficacy in three global Phase 2 trials across PD-L1 expression levels. Together with our partner BMS, we are continuing to advance pumitamig in ongoing pivotal and novel-novel combination trials with the goal of delivering better outcomes for more patients.”

“We are committed to advancing the science of lung cancer with pumitamig and improving on the standard of care for people with this challenging disease,” said Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb. “With one of the broadest registrational programs in the class, we are focused on accelerating the development of pumitamig together with BioNTech, with the goal of delivering meaningful benefit to patients, including those who have been left behind by current therapies.”

BioNTech and BMS are advancing a broad development plan for pumitamig in non-small cell lung cancer across disease stages and subgroups. In addition to the ongoing global ROSETTA Lung-02 trial, which is currently recruiting for the Phase 3 part of the trial, there are two additional global Phase 3 clinical trials in NSCLC currently enrolling. These include ROSETTA Lung-201 (NCT07361497), evaluating pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III NSCLC; and ROSETTA Lung-202 (NCT07361510), evaluating pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 ≥ 50% NSCLC. Pumitamig is also being investigated in combination with other novel investigative treatments for NSCLC, including in combination with investigational antibody-drug conjugates (“ADCs”) and other modalities.

About ROSETTA Lung-02
The global Phase 2/3 ROSETTA Lung-02 trial (NCT06712316) is evaluating pumitamig (BNT327/ BMS986545) in combination with chemotherapy in patients with first-line treatment of non-squamous and squamous non-small cell lung cancer without actionable genomic alterations and with any level of PD-L1 expression. In the Phase 2 dose-optimization part of the trial, patients were randomized 1:1 to 1400 mg or 2000 mg pumitamig plus histology-specific chemotherapy Q3W (non-squamous: carboplatin + pemetrexed; squamous: carboplatin + paclitaxel). The primary endpoints of the Phase 2 part of the trial are objective response rate (ORR) per investigator’s assessment (RECIST 1.1), best percentage change in tumor size from baseline, and safety. Key secondary endpoints include duration of response (DOR) and disease control rate (DCR). The Phase 3 part of the trial will evaluate pumitamig plus chemotherapy versus pembrolizumab plus chemotherapy. Based on the totality of the data, a pumitamig 1500 mg flat dose Q3W plus chemotherapy was selected for further evaluation in the Phase 3 part. The primary endpoint of the Phase 3 part of the trial is progression free survival (PFS) assessed by blinded independent central review (BICR). Key secondary endpoints include overall survival (OS), ORR, DOR.

About Pumitamig
Pumitamig is an investigational bispecific immunomodulator, jointly developed by BioNTech and BMS, designed to cooperatively bind to PD-L1 and VEGF-A. It is aimed at restoring the immune system’s ability to recognize and destroy tumor cells while simultaneously cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), preventing them from growing and proliferating. By anchoring to PD-L1 receptors on tumor cells, we believe pumitamig localizes VEGF-A blockade within the tumor microenvironment, potentially enhancing antitumor activity while minimizing systemic exposure.

More than 2,000 patients have been treated with pumitamig in clinical trials to date. Seven global Phase 3 trials with registrational potential are currently ongoing, evaluating pumitamig plus chemotherapy compared to standard of care treatments, in first-line small cell lung cancer (ROSETTA LUNG-01, NCT06712355); first-line non-small cell lung cancer (ROSETTA LUNG-02, NCT06712316); unresectable stage III non-small cell lung cancer (ROSETTA Lung-201, NCT07361497); first-line advanced PD-L1 ≥ 50% non-small cell lung cancer (ROSETTA Lung-202, NCT07361510); first-line triple-negative breast cancer (ROSETTA BREAST-01, NCT07173751); first-line microsatellite stable colorectal cancer (ROSETTA CRC-203, NCT07221357); and first-line gastric cancer (ROSETTA GASTRIC-204, NCT07221149). Pumitamig is also being explored in 10+ novel-novel combination trials with ADCs and other novel modalities, with the aim of expanding its role across tumor types and identifying additional pivotal opportunities.

About NSCLC
Non-small cell lung cancer (NSCLC) covers all epithelial lung cancers other than small cell lung cancer and includes squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung. It is the most common type of lung cancer, accounting for approximately 85% of cases, and is the leading cause of cancer-related deaths worldwide.² Scientific advances have transformed the treatment of NSCLC, improving outcomes for many patients. However, NSCLC remains an aggressive disease with a poor prognosis and a 5-year survival rate of 18 to 22% in advanced stages.³ Patients with low levels of PD-L1 expression typically do not respond well to checkpoint inhibitor-based regimens creating a significant unmet need for new treatment options that provide durable responses to a broad range of patients.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s collaboration with Bristol Myers Squibb (BMS); BioNTech and BMS’s ability to successfully co-develop and co-commercialize pumitamig (also known as BNT327 or BMS986545), if approved; the rate and degree of market acceptance of pumitamig, if approved; the initiation, timing, progress, and results of BioNTech’s research and development programs, including BioNTech’s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential indications in which pumitamig may be approved, if at all; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s product candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about Bristol Myers Squibb’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to the collaboration with BioNTech may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that future study results may not be consistent with the results to date, that pumitamig (also known as BNT327 or BMS986545) alone or in combination with chemotherapy may not achieve its primary study endpoint or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether pumitamig alone or in combination with chemotherapy will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by Bristol Myers Squibb’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

CONTACTS

BioNTech
Media Relations
Jasmina Alatovic
Media@biontech.de

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de   

Bristol Myers Squibb
Media Relations
media@bms.com  

Investor Relations
investor.relations@bms.com  

1. Mariniello A et al. BioDrugs, 2025 Feb 15;39(2):215–235.
2. Lin Z et al. Medicine (Baltimore). 2025 Jul 25;104(30):e43300.
3. Liu SV et al. Immunotherapy. 2025 Oct;17(14):1005-1013. 

FAQ

What did BioNTech (BNTX) announce about pumitamig in the ROSETTA Lung-02 NSCLC trial on May 30, 2026?

BioNTech announced interim Phase 2 data showing high response rates for pumitamig plus chemotherapy in first-line advanced non-small cell lung cancer. According to BioNTech, confirmed objective response rates reached 57.1% in non-squamous and 68.4% in squamous NSCLC, with a 100% disease control rate.

What were the key efficacy results for pumitamig by PD-L1 expression level in the BioNTech (BNTX) ROSETTA Lung-02 trial?

Pumitamig plus chemotherapy showed notable activity across PD-L1 expression levels in advanced NSCLC. According to BioNTech, cORR was 47.6% for TPS <1%, 77.8% for TPS 1–49%, and 100% for TPS ≥50%, indicating responses across biomarker-defined subgroups.

How did the different pumitamig dose levels perform in the Phase 2 part of the ROSETTA Lung-02 NSCLC study?

Both pumitamig dose levels showed anti-tumor activity, with higher responses at the lower dose. According to BioNTech, the lower dose achieved cORR of 63.6% in non-squamous and 72.7% in squamous NSCLC, supporting continued evaluation at this dose level.

What safety profile was reported for pumitamig plus chemotherapy in BioNTech’s (BNTX) ROSETTA Lung-02 interim analysis?

Pumitamig plus chemotherapy demonstrated what was described as a manageable safety profile with low discontinuation. According to BioNTech, Grade ≥3 treatment-related adverse events occurred in 48.8% of patients, with 23.3% considered pumitamig-related and treatment discontinuation in 9.3% of patients.

What immune-related and bleeding adverse events were seen with pumitamig in the BioNTech (BNTX) lung cancer trial?

The regimen was associated with immune-related and bleeding events in a subset of patients. According to BioNTech, immune-related AEs occurred in 37.2% of patients, Grade ≥3 irAEs in 4.7%, and bleeding events in 20.9%, including one Grade 3 bleeding episode.

What Phase 3 trials are evaluating pumitamig for non-small cell lung cancer according to BioNTech (BNTX)?

Pumitamig is being studied in three global Phase 3 NSCLC trials. According to BioNTech, these include the pivotal Phase 3 part of ROSETTA Lung-02, ROSETTA Lung-201 versus durvalumab in unresectable stage III NSCLC, and ROSETTA Lung-202 versus pembrolizumab in first-line PD-L1 ≥50% disease.

How might pumitamig’s bispecific PD-L1xVEGF-A mechanism be relevant for BioNTech (BNTX) investors following the ROSETTA Lung-02 data?

Pumitamig targets PD-L1 and VEGF-A with a single bispecific immunomodulator in advanced NSCLC. According to BioNTech, interim Phase 2 data showed robust responses across histologies and PD-L1 levels, supporting further development in multiple Phase 3 programs that could influence BioNTech’s oncology portfolio.